Entry into a Material Definitive Agreement · Regulation FD Disclosure
Item 1.01 Entry into a Material Definitive Agreement. On August 4, 2026, Twist Bioscience Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co.…
Filed Aug 5, 2026Accepted Aug 5, 2026, 5:27 PM EDTCIK 1581280Accession 0001104659-26-091280
At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal - more experiments, more iterations, more chances for remarkable discoveries.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 1.01Item 1.01 - Entry into Material Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On August 4, 2026, Twist Bioscience Corporation (the “Company”)
entered into an underwriting agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, William Blair &
Company, L.L.C., Leerink Partners LLC, and Guggenheim Securities, LLC, as representatives of the several underwriters named therein (collectively,
the “Underwriters”), pursuant to which the Company agreed to issue and sell 3,125,000 shares of its common stock to the Underwriters
(the “Offering”). The Shares will be sold to the Underwriters at a public offering price of $96.00 per share, less the underwriting
discount and commissions. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for
30 days, to purchase up to an additional 468,750 shares of its common stock. On August 5, 2026, the Underwriters exercised their option
to purchase all 468,750 additional shares of common stock (the “Option Shares”) at a price per share of $96.00, less the underwriting
discount and commissions.
The net proceeds to the Company from the Offering, including from the
exercise of the Underwriters’ option to purchase the Option Shares in full, are expected to be approximately $327.1 million,
after deducting underwriting discounts and commissions and estimated Offering expenses payable by the Company. The Offering is expected
to close on or about August 6, 2026, subject to customary closing conditions.
The Offering is being made pursuant to the Company’s automatic
shelf registration statement on Form S-3 (No. 333-296897) and the base prospectus included therein (the “Registration Statement”),
which was filed with the Securities and Exchange Commission (the “SEC”) on June 18, 2026, and became automatically effective
upon filing, the preliminary prospectus supplement, dated August 4, 2026, filed with the SEC pursuant to Rule 424(b)(5) under the Securities
Act of 1933, as amended (the “Securities Act”), and the final prospectus supplement, dated August 4, 2026, filed with the
SEC pursuant to Rule 424(b)(5) of the Securities Act.
The Underwriting Agreement contains customary representations and warranties,
conditions to closing, market standoff provisions, termination provisions and indemnification obligations, including for liabilities under
the Securities Act.
The Underwriting Agreement is attached hereto as an exhibit to provide
interested persons with information regarding its terms, but is not intended to provide any other factual information about the Company.
The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of the Underwriting
Agreement as of specific dates indicated therein, were solely for the benefit of the parties to the Underwriting Agreement, and may be
subject to limitations agreed upon by the parties, including being qualified by confidential disclosures exchanged between the parties
in connection with the execution of the Underwriting Agreement.
The foregoing description of the Underwriting Agreement does not purport
to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement. A copy of the Underwriting
Agreement is filed with this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference.
A copy of the opinion and consent of Orrick, Herrington &
Sutcliffe LLP relating to the validity of the shares issued in connection with the Offering is filed herewith as Exhibit 5.1 and Exhibit
23.1, respectively.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On August 4, 2026, the Company issued a press release to announce a
proposed offering of $250.0 million of shares pursuant to the Registration Statement (the “Offering Press Release”). A copy
of the Offering Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On August 4, 2026, the Company also issued a press release to announce
that it had priced an upsized $300.0 million offering (the “Pricing Press Release”). A copy of the Pricing Press Release is
attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Filed exhibits (2)
EX-99.1 (by filename) tm2622018d2_ex99-1.htm
EX-99.1
4
tm2622018d2_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
Twist Bioscience Announces Proposed Public Offering
of $250.0 Million of Common Stock
SOUTH SAN FRANCISCO, Calif. - August 4, 2026 - Twist Bioscience
Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten
public offering of $250.0 million of shares of its common stock. In addition, Twist intends to grant the underwriters a 30-day option
to purchase up to an additional $37.5 million of shares of its common stock. All of the shares of common stock to be sold in the proposed
offering are being offered by Twist. The proposed offering is subject to market and other conditions, and there can be no assurance
as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.
Twist intends to use the net proceeds from the proposed offering, together
with its existing cash, cash equivalents and marketable securities, to fund research and development investments, expansion of manufacturing
capacity, product offerings and the remainder for working capital and other general corporate purposes.
Gol…
Open exhibit ↗EX-99.2 (by filename) tm2622018d2_ex99-2.htm
EX-99.2
5
tm2622018d2_ex99-2.htm
EXHIBIT 99.2
Exhibit 99.2
Twist Bioscience Announces Pricing of Upsized
$300.0 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. - August 4,
2026 - Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced
the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per
share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist
from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $300.0
million. In addition, Twist has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of common stock
at the public offering price, less underwriting discounts and commissions. The offering is expected to close on August 6, 2026, subject
to the satisfaction of customary closing conditions.
Twist intends to use the net proceeds from the
offering, together with its existing cash, cash equivalents and marketable securities, to fund research and dev…